Morales-Cartagena A, Lalueza A, López-Medrano F, Juan RS, Aguado JM. Treatment of methicillin-resistant Staphylococcus aureus infections: Importance of high vancomycin minumum inhibitory concentrations. World J Clin Infect Dis 2015; 5(2): 14-29 [DOI: 10.5495/wjcid.v5.i2.14]
Corresponding Author of This Article
Dr. Alejandra Morales-Cartagena, Infectious Diseases Unit, Department of Medicine, University Hospital 12 de Octubre, Av. Córdoba km 5.400, 28041 Madrid, Spain. a.morales.cartagena@gmail.com
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Infect Dis. May 25, 2015; 5(2): 14-29 Published online May 25, 2015. doi: 10.5495/wjcid.v5.i2.14
Treatment of methicillin-resistant Staphylococcus aureus infections: Importance of high vancomycin minumum inhibitory concentrations
Alejandra Morales-Cartagena, Antonio Lalueza, Francisco López-Medrano, Rafael San Juan, José María Aguado
Alejandra Morales-Cartagena, Antonio Lalueza, Francisco López-Medrano, José María Aguado, Rafael San juan, Infectious Diseases Unit, Department of Medicine, University Hospital 12 de Octubre, 28041 Madrid, Spain
Author contributions: Morales-Cartagena A and Lalueza A were the main authors in writing the draft version; López-Medrano F and Aguado JM principal physicians involved in the critical revision of the manuscript; all the authors approved the final version of the manuscript.
Conflict-of-interest: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Alejandra Morales-Cartagena, Infectious Diseases Unit, Department of Medicine, University Hospital 12 de Octubre, Av. Córdoba km 5.400, 28041 Madrid, Spain. a.morales.cartagena@gmail.com
Telephone: +34-91-3908247 Fax: +34-91-3908112
Received: July 3, 2014 Peer-review started: July 4, 2014 First decision: July 29, 2014 Revised: February 26, 2015 Accepted: March 5, 2015 Article in press: March 9, 2015 Published online: May 25, 2015
Core Tip
Core tip: The emergence of increasing vancomycin-resistance in Staphylococcus aureus (SA) isolates, has stirred up the basis of therapeutic approach in staphylococcal infections. Complete vancomycin-resistance is acquired through plasmid transmission of enterococcal gene vanA. However, the development of strains with gradual loss of vancomycin-susceptibility seems to be related to conformational bacterial changes and affects its pathogenicity and even its susceptibility to other antimicrobials (other than vancomycin). It has been observed that the impact of diminished vancomycin susceptibility could not only affect methicillin-resistant SA but has also been related to worse prognosis in methicillin-sensitive SA infections. There is yet much to explore to better define the impact of higher vancomycin minimum inhibitory concentration in staphylococcal infections.
